Cipla Gets One Form 483 Observation For Bengaluru Unit

Cipla Ltd. has received one Form 483 observation from the US Food and Drug Administration for its manufacturing facility in Bommasandra, Bengaluru. The US regulator inspected the unit between Monday and Friday.

Cipla said it will address the issue raised by the FDA within the stipulated time.